Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oxidative stress-induced growth inhibitor family member 2 (OSGIN2)
- Target
- OSGIN2
- Molecular classification
- Other (belongs to the OSGIN gene family; may possess growth factor-like activity but is not classified under classical families such as receptor, ion channel, or enzyme)
01
Overview
Oxidative stress-induced growth inhibitor family member 2 (OSGIN2) is a protein-coding gene that is part of a small gene family involved in the cellular oxidative stress response. OSGIN2 is predicted to have growth factor activity and negatively regulate cell growth, apoptosis, and autophagy. It is expressed in diverse tissues and is implicated in cancer progression, especially gastric and colorectal cancer; high levels of OSGIN2 correlate with poor prognosis. While OSGIN1 has defined enzymatic activity, OSGIN2’s biochemistry remains less clear, but it is critical in cell cycle regulation, osteogenesis inhibition under oxidative stress, and possibly meiosis/maturation of germ cells. OSGIN2 is not currently categorized as a classical receptor or enzyme, but is increasingly recognized as a prognostic marker and candidate therapeutic target in oncology and diseases related to oxidative stress misregulation.
- Other names
- C8orf1hT41oxidative stress-induced growth inhibitor family member 2OSGIN2HT41
02
Biological functions
Cell proliferationApoptosisAutophagyNegative regulation of cell growthResponse to oxidative stressMeiosis or maturation of germ cells (potential)Negative regulation of osteogenesis under oxidative stress
03
Disease associations
Cancer (including gastric cancer, colorectal cancer, glioblastoma multiforme, kidney renal clear cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, pancreatic cancer, and others)Other diseases associated with oxidative stress (e.g., osteoporosis, as negative regulator in stem cells under stress)Urethra clear cell adenocarcinomaUrethra adenocarcinoma
04
Biomarkers
Patient selection and prognosis is possible for multiple cancers (OSGIN2 identified as a prognostic biomarker in glioblastoma, kidney renal clear cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, pancreatic cancer, colorectal cancer, and gastric cancer)
Beyond the preview
Go deeper on Oxidative stress-induced growth inhibitor family member 2 (OSGIN2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxidative stress-induced growth inhibitor family member 2 (OSGIN2).